Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial

DOI Full Paper Access

45

Citations

13

References

2019

Year

Fernando Torres, Harrison W. Farber, Arsen Ristić, Vallerie V. McLaughlin, John Adams, Jinkun Zhang, Preston Klassen, William Shanahan, John S. Grundy, Ines Hoffmann,

European Respiratory Journal

Abstract

Ralinepag reduced PVR compared with placebo in PAH patients on mono (41%) or dual combination (59%) background therapy.

References

	Year	Citations

Page 1